Table 1.
Patient Characteristics
| Total | |
|---|---|
| Clinical characteristics, n | 55 |
| • Age, y, median (IQR) | 8.7 (2.4–13.8) |
| • Male sex, n (%) | 29 (53) |
| Underlying disease | |
| • Cancer, n (%) | 25 (45.5) |
| • HSCT, n (%) | 15/25 (60) |
| • Critical paediatric patients, n (%) | 14 (25.5) |
| • Critical newborns, n (%) | 5 (9) |
| • Primary immunodeficiencies, n (%) | 5 (9) |
| • Solid organ transplant, n (%) | 3 (5.5) |
| • Other, n (%) | 3 (5.5) |
| Clinical situationa | |
| • Risk of IFI, n (%) | 27 (49) |
| • Suspicion of IFI, n (%) | 6 (11) |
| • Possible IFI, n (%) | 14 (25) |
| • Probable IFI, n (%) | 2 (4) |
| • Proven IFI, n (%) | 6 (11) |
| Microorganisms | |
| • Candida spp. | 2/6 |
| • Moulds | 4/6 |
Abbreviations: IFI invasive fungal infection
aIFI category was defined according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) definitions